FDA BLA · BLA761149

ENSPRYNG

satralizumab

Sponsor: GENENTECH

What this page does not claim

A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.

APPLICATION
BLA761149
TYPE
BLA
ORIGINAL APPROVAL
2020-08-14
LATEST ACTION
2026-10-15
ROUTE
SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

ENSPRYNGPrescription
SATRALIZUMAB 120MG/ML · INJECTABLE · INJECTION

Approval history

2026-10-15Efficacy · Supplement 8 · priority — Letter ↗AP
2026-06-10Manufacturing (CMC) · Supplement 7AP
2022-09-14Labeling · Supplement 5 · standard — Label ↗AP
2021-05-03Labeling · Supplement 2 · standard — Letter ↗AP
2020-08-14Type 1 - New Molecular Entity · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →